Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Psychiatric disorders – page 3

  • 548 clinical trials
  • 257 recruiting
  • 147 conditions
  • 26 countries

Conditions in this area

147 conditions with trials, the busiest first

Dementia Alzheimer's type87Major depression57Schizophrenia40Depression35Narcolepsy19Cognitive disorder18Bipolar disorder16Autism spectrum disorder15Insomnia15Post-traumatic stress disorder14Psychotic disorder14Drug use disorder13Alcohol use disorder12Attention deficit hyperactivity disorder9Dementia9Obstructive sleep apnoea syndrome9Brain injury8Irritable bowel syndrome8Phenylketonuria8Bipolar I disorder7Drug dependence7Hypersomnia7Lennox-Gastaut syndrome7Anorexia nervosa6+123

Clinical trials in Psychiatric disorders

548 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

548 clinical trials

Depression+1

Recruiting

Efficacy of high- and low-dose psilocybin in preventing relapse in adults with severe alcohol use disorder and depressive symptoms after detoxification

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Psilocybine
  • Sponsor:Centre Hospitalier Universitaire De Nimes

Schizophrenia+1

Recruiting

Long‑Term Safety and Tolerability of KarXT in Adolescents with Schizophrenia and of KarXT + KarX‑EC in Children and Adolescents with Autism‑Related Irritability

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dementia of the Alzheimer's type with delusions

Recruiting

Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Fesoterodine
  • Sponsor:Maplight Therapeutics Inc.

Insomnia+1

Recruiting

Daridorexant for Insomnia in Patients with Major Depressive Disorder and Moderate to Severe Insomnia

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daridorexant
  • Sponsor:Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Schizophrenia

Recruiting

A study to assess the safety and effectiveness of GXV813 in hospitalized adults with schizophrenia

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:GXV813
  • Sponsor:Novartis Pharma AG

Lennox-Gastaut syndrome

Recruiting

A study to evaluate the effectiveness and safety of clemizole hydrochloride as an additional treatment for patients with Lennox-Gastaut syndrome

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Clemizole Hydrochloride
  • Sponsor:Epygenix Therapeutics Inc.

Fragile X syndrome

Recruiting

A study to evaluate the safety of MRM-3379 in men with Fragile X Syndrome

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Sponsor:Mirum Pharmaceuticals Inc.

Schizophrenia

Recruiting

A study to evaluate the efficacy and safety of trospium chloride and xanomeline tartrate for the treatment of schizophrenia in adolescents aged 13 to 17 years

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Rett syndrome

Recruiting

A Phase 3 Study of Fenfluramine Hydrochloride for Safety and Efficacy in Patients with Rett Syndrome

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:UCB Biosciences Inc.

Drug dependence

Recruiting

Study of semaglutide to reduce cannabis use in adults with cannabis use disorder

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Region Hovedstaden

Obstructive sleep apnoea syndrome

Recruiting

A study to evaluate the effects of zenagamtide in people with overweight or obesity and obstructive sleep apnoea not treated with positive airway pressure

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Neurodevelopmental disorder

Recruiting

A study to evaluate the effects of N-Acetyl-L-Leucine in patients with CACNA1A disorders

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:L-Acetylleucine
  • Sponsor:IntraBio Inc

Substances studied in this area

The therapies tested most often in Psychiatric disorders trials.

Sodium Chloride25 clinical trialsTrospium Chloride18 clinical trialsXanomeline Tartrate17 clinical trialsCannabidiol15 clinical trialsDry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol14 clinical trialsFlorquinitau (18F)14 clinical trialsOxytocin13 clinical trialsAripiprazole12 clinical trialsFlorbetaben (18F)12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.